One of Ann Arbor’s most exciting educational events is back. One Day Closer gives individuals and families an up-close look at one of the world’s leading cancer research facilities and what its internationally-recognized scientists and colleagues are doing to discover the cure for cancer.
Patients with chronic myelomonocytic leukemia have limited treatment options, and those that exist are effective only in fewer than half of patients. Now, a new study identifies a panel of genetic markers that predicted which tumor samples would likely respond to treatment.
Researchers have developed a new drug candidate that shows potential in laboratory studies against a rare type of acute leukemia. And additional studies suggest the same compound could play a role in prostate cancer treatment as well.
The average lifetime risk of ovarian cancer is approximately 1.37 percent in non-Hispanic white women in the United States, but there are women at substantially higher and lower risk, according to the researchers, led by Celeste Leigh Pearce, associate professor of epidemiology.
In a randomized phase 3 trial, adrenal cancer patients receiving the investigational drug linsitinib fared no better than patients receiving a placebo. But the researchers noticed a small subset of patients who had significant response and remained on the drug for an extended time.
Theodore S. Lawrence, M.D., Ph.D., has been named the director of the University of Michigan Comprehensive Cancer Center. Lawrence, who is also chair of radiation oncology, succeeds founding director Max S. Wicha, M.D.